Invention Grant
- Patent Title: Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
-
Application No.: US15977470Application Date: 2018-05-11
-
Publication No.: US10538524B2Publication Date: 2020-01-21
- Inventor: Mathew Calder , Nicolas Guisot
- Applicant: Loxo Oncology, Inc.
- Applicant Address: US CT Stamford
- Assignee: Loxo Oncology Inc.
- Current Assignee: Loxo Oncology Inc.
- Current Assignee Address: US CT Stamford
- Agent James B Myers
- Priority: GB1410430.1 20140611
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; A61K45/06 ; A61P35/00
Abstract:
This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Public/Granted literature
- US20190119281A1 Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase Public/Granted day:2019-04-25
Information query
